Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Open-Label, Phase 2 Clinical Trial

Blood (2019) 134 (Supplement_1): 2838.

https://doi.org/10.1182/blood-2019-126481

Published: 2019

Journal Articles

Evaluation of the Effectiveness and Safety of Pixantrone for the Treatment of Multiply Relapsed or Refractory Aggressive Non Hodgkin B-Cell Lymphoma in an Ongoing International Registry

Pier Luigi Zinzani, MD PhD, Belén Navarro, MD, Juan-Manuel Sancho, MD PhD, Begoña Soler, MD, Silvina Grasso Cicala, PhD, Lorena Yapur, MD, Mario Spione, PharmD, MSc

Blood (2017) 130 (Supplement 1): 5228.

https://doi.org/10.1182/blood.V130.Suppl_1.5228.5228

Published: 2017

Journal Articles

Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma: Report on an Ongoing Phase II Trial (GOAL)

Georg Hess, MD, Andreas Hüttmann, MD, Reinhard Marks, MD, Mathias Witzens-Harig, MD, Martin H. Dreyling, MD PhD, Andreas Viardot, Georg Lenz, MD, Christiane Pott, Annegret Kuhn, MD, Christian Ruckes, Matthias Theobald, MD, Ulrich Keller

Blood (2016) 128 (22): 5392.

https://doi.org/10.1182/blood.V128.22.5392.5392

Published: 2016

Journal Articles

Retrospective Study Evaluating Hematological Remission Rates and Survival in Chinese Adults with Relapsed or Refractory (r/r) Philadelphia Chromosome Negative (Ph - ) B-Precursor Acute Lymphoblastic Leukemia (ALL)

Jun Ma, MD, Ting Liu, MD, Jie Jin, MD PhD, Jianda Hu, MD PhD, Qifa Liu, MD, Jianxiang Wang, MD, Zhixiang Shen, MD, Xin Du, MD PhD, Bin Jiang, MD, Xianhua Meng, PhD

Blood (2016) 128 (22): 5198.

https://doi.org/10.1182/blood.V128.22.5198.5198

Published: 2016

Journal Articles

Conventional 7+3 Consolidation Is Equal in Long-Term Outcome to High Dose ARA-C in Case of the High Total Doses of Different Anthracyclines/Anthracenedione in Induction/Consolidation - the Interim Results of Russian Randomized Multicenter AML-10 Trial

Blood (2014) 124 (21): 3667.

https://doi.org/10.1182/blood.V124.21.3667.3667

Published: 2014

Journal Articles

Combined Targeting of β-Catenin and FLT-3 Is Synergistically Lethal Against Cultured and Primary AML Blast Progenitor Cells Expressing FLT3 Internal Tandem Duplication (ITD)

Saikat Saha, PhD, Warren Fiskus, PhD, Sunil Sharma, Bhavin Shah, Anna T Rogojina, Santhana G. T. Devaraj, PhD, Baohua Sun, MD PhD, Christopher Leveque, MD, Youli Zu, MD PhD, Swaminathan Padmanabhan Iyer, MD, Kapil N. Bhalla, MD

Blood (2014) 124 (21): 618.

https://doi.org/10.1182/blood.V124.21.618.618

Published: 2014

Journal Articles

In-Vitro Actvity of Pixantrone (PIX) in Plasma Cell Leukaemia (PCL) and Early Clinical Activity in a Pixantrone–Pomalidomide–Dexamethasone (PiPoD) Combination

Ella Willenbacher, MD, Wolfgang Willenbacher, MD, Gunther Gastl, Prof., Dr., Irmgard Verdorfer, MDPhD, Brigitte Kircher, PhD

Blood (2014) 124 (21): 5732.

https://doi.org/10.1182/blood.V124.21.5732.5732

Published: 2014

Journal Articles

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Blood (2014) 124 (21): LBA-6.

https://doi.org/10.1182/blood.V124.21.LBA-6.LBA-6

Published: 2014

Journal Articles

A Novel Emodin Derivative Inhibited Imatinib-Resistant Chronic Myelogenous Leukemia Cells.

Jianda Hu, PhD, Jing Li, PhD, Wenfeng Wang, Tingbo Liu, PhD, Jing Zheng, PhD

Blood (2012) 120 (21): 2774.

https://doi.org/10.1182/blood.V120.21.2774.2774

Published: 2012

Journal Articles

Pre-Clinical Efficacy of Combined Therapy with Novel β-Catenin Antagonist BC2059 and Histone Deacetylase Inhibitor Against Cultured and Primary AML Blast Progenitor Cells

Kapil Bhalla, MD, Warren Fiskus, Ph.D., Stephen K. Horrigan, PhD, Sunil Abhyankar, MD, Joseph McGuirk, DO, Sunil Sharma, MD

Blood (2012) 120 (21): 287.

https://doi.org/10.1182/blood.V120.21.287.287

Published: 2012

Journal Articles

Treatment with β-Catenin Antagonist BC2059 Exerts Single Agent Efficacy and Exerts Improved Activity with Tyrosine Kinase Inhibitor (TKI) or Pan-Histone Deacetylase (HDAC) Inhibitor Against Human CML and Myeloproliferative Neoplasm (MPN) Progenitor Cells

Warren Fiskus, PhD, Jacqueline Smith, MS, Uma Mudunuru, MS, Stacey Hembruff, MS, Ruben Reyes, MD, Sunil Abhyankar, MD, Joseph McGuirk, DO, Omar S. Aljitawi, MD, Siddhartha Ganguly, MD, Stephen K. Horrigan, PhD, Sunil Sharma, MD, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 65.

https://doi.org/10.1182/blood.V118.21.65.65

Published: 2011

Journal Articles

Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment

Emanuela Salvatorelli, MD, Odalys Gonzalez Paz, PhD, Elvio Covino, MD, Massimo Chello, MD, Jack Singer, MD, Pierantonio Menna, PhD, Giorgio Minotti, MD

Blood (2011) 118 (21): 4966.

https://doi.org/10.1182/blood.V118.21.4966.4966

Published: 2011

Journal Articles

A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT)

Matthew J. Matasar, MD, MS, Myron S. Czuczman, MD, Maria Alma Rodriguez, MD, Michael Fennessy, BSc, PhD, Thomas C. Shea, MD, Gary Spitzer, MD, Izidore S Lossos, MD, Mohamed A. Kharfan-Dabaja, MD, Robin Joyce, MD, Luis Fayad, MD, Qiming Liao, PhD, Klaus Edvardsen, MD, PhD, Steen Lisby, MD, DMSc, Craig H. Moskowitz, MD

Blood (2011) 118 (21): 957.

https://doi.org/10.1182/blood.V118.21.957.957

Published: 2011

Journal Articles

CPOP-R Versus CHOP-R As First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study

Raoul Herbrecht, David MacDonald, MD, FRCPC, Florian Weissinger, MD, Martin Wilhelm, MD, Charles Holladay, MS, MD, Nam H. Dang, MD, PhD, Peter Holman, MD, Paul Cernohous, MS, Jack Singer, MD, Richard H. van der Jagt, MD, FRCPC

Blood (2011) 118 (21): 1605.

https://doi.org/10.1182/blood.V118.21.1605.1605

Published: 2011

Journal Articles

Treatment of Burkitt's Like Lymphoma: A Single Institution Case Series

Vishal Ranpura, MD, Shilpan S. Shah, MD

Blood (2011) 118 (21): 4962.

https://doi.org/10.1182/blood.V118.21.4962.4962

Published: 2011

Journal Articles

A Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Combination with Rituximab and/or Bendamustine In Patients with Relapsed or Refractory B-Cell Malignancies.

Ian W. Flinn, MD, PhD, Marshall T. Schreeder, Nina Wagner-Johnston, Ralph V. Boccia, MD, John P. Leonard, MD, Steven E. Coutre, Leanne M. Holes, Sissy Peterman, Albert S. Yu, MD

Blood (2010) 116 (21): 2832.

https://doi.org/10.1182/blood.V116.21.2832.2832

Published: 2010

Journal Articles

Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.

Ruth Pettengell, FRACP, PhD, Pier Luigi Zinzani, MD, PhD, Geetha Narayanan, MD, Fernando Hurtado de Mendoza, MD, Raghunadharao Digumarti, MD, Henry Gomez, MD, Bertrand Coiffier, MD, PhD, Gary Schiller, MD, David A. Rizzieri, MD, Paul Cernohous, MS, Lixia Wang, PhD, Jack Singer, MD

Blood (2010) 116 (21): 2833.

https://doi.org/10.1182/blood.V116.21.2833.2833

Published: 2010

Journal Articles

Patients with FLT3/ITD AML May Benefit From Allogeneic Transplant In First Remission: Outcomes From a Consecutive Series of Patients at a Single Institution

Amy E. DeZern, MD, Anthony Sung, MD, Sharon Kim, MD, Hua-Ling Tsai, MS, Jeanne Kowalski, PhD, B. Douglas Smith, MD, Judith E. Karp, MD, Steven D. Gore, M.D., Ephraim Fuchs, MD, Michael A McDevitt, MD, PhD, Leo Luznik, MD, Richard J. Jones, MD, Mark J. Levis, MD, PhD

Blood (2010) 116 (21): 2172.

https://doi.org/10.1182/blood.V116.21.2172.2172

Published: 2010

Journal Articles

Pixantrone Dimaleate (PIX) and Comparators In the Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (aNHL): An Analysis of Response and Survival by Gender and Age

Jack Singer, MD, Paul Cernohous, MS, Gabor Jurida, MD, Lixia Wang, PhD, Christine Kuepfer, MS, Ruth Pettengell, FRACP, PhD

Blood (2010) 116 (21): 4883.

https://doi.org/10.1182/blood.V116.21.4883.4883

Published: 2010

Journal Articles

Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Brad Kahl, MD, John C. Byrd, MD, Ian W. Flinn, MD, PhD, Nina Wagner-Johnston, MD, Stephen Spurgeon, MD, Don M Benson, Jr, MD, Richard R. Furman, MD, Jennifer R Brown, MD, PhD, Steven Coutre, MD, Brian Lannutti, PhD, Neil A. Giese, Ph.D., Roger G Ulrich, Ph.D., Heather K Webb, Ph.D., Sissy Peterman, Leanne Holes, Albert S Yu, MD

Blood (2010) 116 (21): 1777.

https://doi.org/10.1182/blood.V116.21.1777.1777

Published: 2010

NARROW

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Open-Label, Phase 2 Clinical Trial

Evaluation of the Effectiveness and Safety of Pixantrone for the Treatment of Multiply Relapsed or Refractory Aggressive Non Hodgkin B-Cell Lymphoma in an Ongoing International Registry

Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma: Report on an Ongoing Phase II Trial (GOAL)

Retrospective Study Evaluating Hematological Remission Rates and Survival in Chinese Adults with Relapsed or Refractory (r/r) Philadelphia Chromosome Negative (Ph - ) B-Precursor Acute Lymphoblastic Leukemia (ALL)

Conventional 7+3 Consolidation Is Equal in Long-Term Outcome to High Dose ARA-C in Case of the High Total Doses of Different Anthracyclines/Anthracenedione in Induction/Consolidation - the Interim Results of Russian Randomized Multicenter AML-10 Trial

Combined Targeting of β-Catenin and FLT-3 Is Synergistically Lethal Against Cultured and Primary AML Blast Progenitor Cells Expressing FLT3 Internal Tandem Duplication (ITD)

In-Vitro Actvity of Pixantrone (PIX) in Plasma Cell Leukaemia (PCL) and Early Clinical Activity in a Pixantrone–Pomalidomide–Dexamethasone (PiPoD) Combination

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

A Novel Emodin Derivative Inhibited Imatinib-Resistant Chronic Myelogenous Leukemia Cells.

Pre-Clinical Efficacy of Combined Therapy with Novel β-Catenin Antagonist BC2059 and Histone Deacetylase Inhibitor Against Cultured and Primary AML Blast Progenitor Cells

Treatment with β-Catenin Antagonist BC2059 Exerts Single Agent Efficacy and Exerts Improved Activity with Tyrosine Kinase Inhibitor (TKI) or Pan-Histone Deacetylase (HDAC) Inhibitor Against Human CML and Myeloproliferative Neoplasm (MPN) Progenitor Cells

Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment

A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT)

CPOP-R Versus CHOP-R As First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study

Treatment of Burkitt's Like Lymphoma: A Single Institution Case Series

A Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Combination with Rituximab and/or Bendamustine In Patients with Relapsed or Refractory B-Cell Malignancies.

Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.

Patients with FLT3/ITD AML May Benefit From Allogeneic Transplant In First Remission: Outcomes From a Consecutive Series of Patients at a Single Institution

Pixantrone Dimaleate (PIX) and Comparators In the Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (aNHL): An Analysis of Response and Survival by Gender and Age

Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only